Evidence map›Paper›PMID 32665438›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo.

Pengfei Wang, Mili R Gajjar, Jian Yu, Neal N Padte, Agegnehu Gettie, James L Blanchard, Kasi Russell-Lodrigue, Laura E Liao, Alan S Perelson, Yaoxing Huang and 1 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. An engineered antibody-lectin conjugate targeting the HIV glycan shield protects humanized mice against HIV challenge.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  17. Review
  18. Article
  19. Engineering of CD8mBio · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Pengfei WangAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.ORCID 0000-0003-2454-7652
Mili R GajjarAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.
Jian YuAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.
Neal N PadteAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.
Agegnehu GettieAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.
James L BlanchardTulane National Primate Research Center, Tulane University, Covington, LA 70433.
Kasi Russell-LodrigueTulane National Primate Research Center, Tulane University, Covington, LA 70433.ORCID 0000-0003-3719-0779
Laura E LiaoTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545.ORCID 0000-0001-6069-2633
Alan S PerelsonTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545.ORCID 0000-0002-2455-0002
Yaoxing HuangAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.
David D HoAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032; dh2994@cumc.columbia.edu.
Aaron Diamond AIDS Research Center · USLos Alamos National Laboratory · USTulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Viral dynamics of rebound and control following early treatment of HIV/SIVP01AI131365 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2017 to 2021
$7.5M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir CellsR01AI129802 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HO, DAVID D · 2017 to 2021
$4.1M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
Bispecific-Antibody-Drug Conjugates for Selective Targeting and Activation of the HIV Latent ReservoirR01AI134328 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HO, DAVID D · 2017 to 2021
$2.7M
Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.R01AI145645 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HO, DAVID D · 2019 to 2023
$2.4M
NIAID NIH HHS P01 AI131365NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI129802NIAID NIH HHS R01 AI134328NIAID NIH HHS R01 AI145645NIH HHS P51 OD011104NIH HHS R01 OD011095
6 · The paper itself

Abstract

In combating viral infections, the Fab portion of an antibody could mediate virus neutralization, whereas Fc engagement of Fc-γ receptors (FcγRs) could mediate an array of effector functions. Evidence abounds that effector functions are important in controlling infections by influenza, Ebola, or HIV-1 in animal models. However, the relative contribution of virus neutralization versus effector functions to the overall antiviral activity of an antibody remains unknown. To address this fundamental question in immunology, we utilized our knowledge of HIV-1 dynamics to compare the kinetics of the viral load decline (ΔVL) in infected animals given a wild-type (WT) anti-HIV-1 immunoglobulin G1 (IgG1) versus those given a Fc-Null variant of the same antibody. In three independent experiments in HIV-1-infected humanized mice and one pivotal experiment in simian-human immunodeficiency virus (SHIV)-infected rhesus macaques, an earlier and sharper decline in viral load was consistently detected for the WT antibody. Quantifications of the observed differences indicate that Fc-mediated effector functions accounted for 25-45% of the total antiviral activity in these separate experiments. In this study, Fc-mediated effector functions have been quantified in vivo relative to the contribution of virus neutralization mediated by the Fab.

Indexed as

AnimalsAntibodies, NeutralizingDisease Models, AnimalHIV-1HIV AntibodiesHIV InfectionsHost-Pathogen InteractionsHumansImmunoglobulin GMiceMice, TransgenicNeutralization TestsReceptors, IgGAntibodies, NeutralizingHIV AntibodiesImmunoglobulin GReceptors, IgGantibodyeffector functionsHIV-1 dynamicsin vivo quantificationneutralization

Identifiers

PMID32665438
PMCPMC7395461
OpenAlexW3042822293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.